10–20 mg/day.
In mouse liver cells, PQQ increased the creation of new mitochondria and cellular respiration (via PGC-1α). The basis of the interest in PQQ for energy and longevity, but it is preclinical (cells/animals), with no clear clinical proof.
View the study (study) →⏱ 3 min read
Pyrroloquinoline quinone, or PQQ, is a small molecule with enzymatic cofactor properties in bacteria and, according to some researchers, in mammals as well (although whether it is essential for humans remains the subject of active scientific debate); its most interesting documented biological profile is the ability to stimulate mitochondrial biogenesis (the generation of new mitochondria in cells) through activation of PGC-1alpha and other cell signaling pathways, an unusual pharmacological property that has positioned it as a supplement of interest for indications where mitochondrial function is critical: cognitive performance, chronic fatigue, cellular aging, and physical endurance performance.
Dietary sources of PQQ are ubiquitous but in very small amounts: kiwi, parsley, green tea, green peppers, papaya, tofu, and other plant foods provide amounts in the nanogram to microgram range per serving; commercial supplements typically provide 10-40 milligrams daily, amounts several orders of magnitude higher than dietary ones, and whose physiological relevance relative to the usual dietary figure is a matter of debate.
The biological mechanism that has generated the most clinical interest is the stimulation of PGC-1alpha, the master transcriptional coactivator of mitochondrial biogenesis; in preclinical models and in some human studies, PQQ increases the number and function of mitochondria in tissues with high energy demand (brain, muscle, heart), an effect consistent with its postulated clinical profile in fatigue, physical performance, and cognitive function, but whose human clinical translation is modest and studies remain small.
In healthy adults and especially in older adults, several small Japanese studies have documented modest improvements in memory and attention with supplementation at 20 mg/day for 8-12 weeks, generally in combination with coenzyme Q10 (another molecule related to mitochondrial function); the effects are modest but consistent with the mitochondrial mechanistic profile.
In mild chronic fatigue and low subjective well-being, several studies have documented subjective improvements with supplementation over weeks to months; the data are preliminary but consistent with the profile of mitochondrial modulation.
In chronic stress and mild sleep disorders, some small Japanese studies have documented improvements in subjective sleep quality and reductions in stress markers with supplementation, an indication with preliminary clinical support.
The doses studied range from 10 to 40 milligrams daily, divided into one or two doses with or without food; typical commercial products contain 10-20 mg per capsule with reasonable absorption profiles; combinations with coenzyme Q10 or ubiquinol are common because of the theoretical synergy between the generation of new mitochondria (PQQ) and their optimal functioning (CoQ10).
Generally well tolerated at the doses studied; the adverse effects described are rare and mild (mild digestive discomfort, occasionally headache); no significant toxicities have been described with use at the usual supplemental doses, although clinical experience with long-term use is relatively limited; people with cancers that depend specifically on mitochondrial function should exercise theoretical caution because of the effect on mitochondrial biogenesis (although there are no clear clinical data suggesting risk); those taking glucose-lowering drugs should monitor blood glucose because of preliminary data suggestive of mild metabolic modulation; in pregnancy and breastfeeding, specific data as a supplement are limited and avoidance is recommended as a precaution; the cost per milligram of PQQ is significantly higher than that of many other supplements, and the cost-effectiveness must be weighed carefully: for most indications of fatigue and cognitive function, interventions with stronger clinical support (creatine, omega-3, sleep optimization, and aerobic exercise) offer better cost-effectiveness than PQQ; as an adjunct in multimodal strategies for people with suspected mitochondrial dysfunction, it may have a place with modest expectations and still-limited clinical support.
Information, not medical advice. Scientific evidence reflects the quality of the studies.